Saturday 17 October 2026
Export SOLV’s income statement to Excel — free account
Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.
85.81
2.05
−2.33%
Follow SOLV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 5 | — |
+8 more TTM periods Free account |
| 33.96% | 34.79% | 38.86% | 37.27% | ||
| 9.78% | 10.01% | 10.82% | 10.61% | ||
ROIC |
13.40% | 13.60% | 14.81% | 16.15% | |
Return on Tangible Assets |
87.28% | 80.45% | 75.94% | 54.33% | |
Average Days of Receivables |
62.90 | 52.13 | 51.91 | 51.09 | |
Free Cash Flow per Share |
(0.68) | (1.17) | (0.06) | 0.29 | |
Free Cash Flow |
(118.00) | (203.00) | (10.00) | 50.00 | |
Capital Expenditures |
(327.00) | (354.00) | (379.00) | (443.00) | |
| Other line items | |||||
Cash ROIC |
(1.12%) | (1.88%) | (0.09%) | 0.42% | |
Accounts Receivable Turnover |
6.19 | 7.21 | 6.90 | 6.71 | |
Accounts Payable Turnover |
5.60 | 5.88 | 5.94 | 6.28 | |
Inventory Turnover |
3.76 | 3.92 | 3.81 | 3.86 | |
Average Days of Payables |
67.94 | 66.63 | 64.73 | 63.28 | |
Days of Inventory on Hand |
100.80 | 103.81 | 100.44 | 99.22 | |
Tax Rate |
(0.15) | (0.15) | (0.09) | (0.09) | |
Research and Development Expense of Revenue |
8.71% | 8.90% | 8.88% | 9.09% | |
Selling, General and Administrative Expense of Revenue |
39.63% | 37.98% | 37.00% | 36.96% | |
Share Based Compensation of Revenue |
2.01% | 1.97% | 1.93% | 1.77% | |
Interest Coverage |
7.80 | 6.91 | 6.29 | 5.44 | |
Operating CF/Net income |
0.15 | 0.11 | 0.24 | 0.32 | |
Depreciation/Fixed assets |
0.32 | 0.32 | 0.37 | 0.39 | |
Capex/Depreciation |
(0.65) | (0.72) | (0.78) | (0.85) | |
Revenue per Share |
48.12 | 47.43 | 47.82 | 48.20 | |
Operating CF per Share |
1.21 | 0.87 | 2.12 | 2.83 | |
Capex per Share |
(1.89) | (2.03) | (2.18) | (2.54) | |
Capex to Sales |
0.04 | 0.04 | 0.05 | 0.05 |
Columns are period end dates